What stage does Dementia Discovery invest at?

Dementia Discovery invests at the Pre-Seed, Seed, Series A, Series B, Series C stages.

Where is Dementia Discovery located?

Dementia Discovery is headquartered in London, GB.

Does Dementia Discovery lead rounds?

Dementia Discovery typically participates in rounds rather than leading them.

Who does Dementia Discovery co-invest with?

Dementia Discovery most often shares deals with SV Health Investors, F-Prime Capital, GV (Google Ventures), among 11 tracked co-investors.

Dementia Discovery

Venture capital

London · Pre-Seed–Series C · 10 people tracked

Also known as Dementia Discovery Fund

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

DDF backs bold entrepreneurs across the full spectrum of company and asset stages within dementia therapeutics, and creates new biotech companies itself where none exist. Its mandate is to interrogate novel hypotheses and expand the breadth of targets and mechanisms for dementia therapies, investing in early-stage projects from target identification onward to translate novel biology into disease-modifying drugs. Covering Alzheimer's and other dementias such as PDD, FTD, ALS and HD, the fund pursues a dual mandate of delivering measurable patient impact and generating strong financial returns, drawing on a network of venture partners, entrepreneurs, scientists and strategic pharmaceutical partners.

Invests inBiotech Digital Health Healthtech Impact & Social Good Longevity Medical Devices Europe Global London United Kingdom United States

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Series C

London, Massachusetts, GB

Leads rounds

Follows

Instruments

Equity

Founded

2015

AUM

$600M

Tracked investments

Team · 10 people

from curated & public directories

Christian Jung· Partner· London, England, United Kingdomin

Christian Jung is a Partner at SV Health Investors, where he co-leads the Dementia Discovery Fund, a group of venture capital funds focused on therapeutics for dementia that has raised over $600 million. He represents the funds on the boards of Amphista Therapeutics, Harness Therapeutics, Leal Therapeutics, and LoQus23 Therapeutics, and has structured and led investments in 15 biotech companies, including Amal Therapeutics and Rigontec. Jung has 20 years of experience in healthcare venture capital and holds a PhD in Molecular Biology/Stem Cell Biology.

c•••@svhealthinvestors.comreveal

Jonathan Behr· Partner

j•••@svhealthinvestors.comreveal

Laurence Barker· Partner

l•••@svhealthinvestors.comreveal

Miles Gerson· Partner at SV Health Investors· USAin 𝕏

Miles Gerson joined SV Health Investors as a partner in 2026 and co-leads the firm's Dementia Discovery Fund (DDF). He previously headed Takeda Ventures, where he oversaw a portfolio of more than 60 private and public life sciences investments and led the corporate venture group's global investment strategy, and also served on an interim basis as Takeda's Head of GI Business Development. Earlier in his career he was in founding management of early-stage companies and led investment diligence for venture and private equity firms in the US and Europe. He holds a JD/MBA from the University of Wisconsin-Madison and Bachelor's and Master's degrees in Neuroscience & Behavioral Studies from Wesleyan University.

Romain Touyé· Partner at SV Health Investors· Cambridge, Massachusetts, United Statesin

Dirk Landgraf· Principal

m•••@svhealthinvestors.comreveal

Dirk Landgraf· Principal· Boston, Massachusettsin

Dirk Landgraf joined SV Health Investors in 2020 and is a Principal on the Dementia Discovery Fund (DDF) team, where he helps form and fund companies developing new medicines for dementia and supports DDF portfolio companies with due diligence and strategic, business development, and operational needs. Before SV, he was an Associate Director in the External Innovation group at Biogen in Cambridge, MA, evaluating business development opportunities across neurological therapeutic areas, and earlier was a Postdoctoral Fellow in Susan Lindquist's lab at the Whitehead Institute at MIT. He holds a PhD from Harvard University's Department of Systems Biology at Harvard Medical School and BSc and MSc degrees in Biochemistry from the Technical University of Munich.

Georgia Frost· Senior Associate· London Area, United Kingdomin

g•••@svhealthinvestors.comreveal

Huiyuan Zhang· Senior Associate

h•••@svhealthinvestors.comreveal

Damian Crowther· Entrepreneur In Residence· Cambridge, England, United Kingdomin

Physician-scientist trained at Cambridge and Oxford specializing in neurology, formerly at AstraZeneca Neuroscience and an EIR at several life-science funds. Focus area: biotech.

What they invest in

from 3 of 4 portfolio companies

Biotech ×3Healthtech ×3Deep Tech ×2Digital Health ×1Medical Devices ×1

HQs:United States×2United Kingdom×1

Investments · 4 tracked

founders shown can be your intro path

Violet Therapeutics, Inc.May 2023

Cambridge, US

Board seatJonathan Behr· per SEC Form D

Co-investorsOno Venture Investment, Inc.SV Health Investors

AviadoBio Websiteaviadobio.com in 𝕏

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)Do Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)Lisa Deschamps(Chief Executive Officer)Graeme Fielder(Chief Operating Officer)Alex Bloom(Chief Development Officer)

Co-investorsAdvent Life Sciences F-Prime Capital LifeArc Ventures Monograph Capital Partners New Enterprise Associates (NEA)

Cerevancecerevance.com in 𝕏

Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.

BiotechDeep TechHealthtech

Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)

Co-investorsForesite Capital GV (Google Ventures)Dementia Discovery Fund SV Life Sciences Lightstone Ventures SV Health Investors +2 more

Therapeuticssvhealthinvestors.com

SV Health Investors is a global private equity and venture capital investment platform specializing in healthcare across biotechnology, medical devices, and healthcare growth equity.

BiotechHealthtechMedical DevicesBoston, US

Co-investorsDementia Discovery Fund

Frequently asked questions

What stage does Dementia Discovery invest at?: Dementia Discovery invests at the Pre-Seed, Seed, Series A, Series B, Series C stages.
What sectors does Dementia Discovery focus on?: Dementia Discovery focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Longevity, Medical Devices.
Where is Dementia Discovery located?: Dementia Discovery is headquartered in London, GB.
Does Dementia Discovery lead rounds?: Dementia Discovery typically participates in rounds rather than leading them.
Who does Dementia Discovery co-invest with?: Dementia Discovery most often shares deals with SV Health Investors, F-Prime Capital, GV (Google Ventures), among 11 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Christian Jung, Dementia Discovery Fund, on building strong companies and value that lasts

SuperReturnTV · Christian Jung · youtube.com

Similar investors

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Tenmile

Tenmile is an Australia-based venture firm investing in health and life sciences companies from seed stage onward, aiming to connect Australian innovation to global markets.

Portfolia

Portfolia operates venture funds designed by and for women, enabling members to invest collectively in innovative companies while learning together through curated content, founder access, and hands-on deal flow.

$10K

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

$540K – $27M

Equitage Ventures, L.L.C.

Equitage Ventures is an early-stage investor providing capital, distribution, and strategic guidance to entrepreneurs addressing the physical, mental, spiritual, and social needs of older adults across the senior care continuum.

$250K – $2.5M